#China #Hangzhou #LifeTech #Zylox-Tonbridge #GL Capital

A Strategic Investment in LifeTech Scientific

On November 6, 2026, Zylox-Tonbridge Medical Technology Co., Ltd., a prominent player in the vascular intervention space, announced its strategic investment in LifeTech Scientific Corporation, a groundbreaking move forged in partnership with GL Capital. This investment highlights the companies' ambition to establish a leading integrated vascular and structural heart intervention platform that can excel in the burgeoning Chinese medtech market.

Uniting Forces: A Comprehensive Therapeutic Portfolio

This strategic collaboration is set to merge Zylox-Tonbridge's revolutionary peripheral vascular and neurovascular businesses with LifeTech's well-established aortic and structural heart operations. The result will be a cohesive and robust portfolio covering four pivotal therapeutic areas. Strengthened by their complementary research and development capabilities, the partnership is geared towards hastening innovation while simultaneously enhancing their global market presence.

Under the terms of the agreement, Zylox-Tonbridge and GL Capital will collectively invest about HK$1.482 billion into LifeTech by means of GL Lighthouse Two Investment Limited. This subsidiary will acquire roughly 16.7% of LifeTech's expanded share capital, effectively making Lighthouse Two the largest single shareholder in LifeTech, with Zylox-Tonbridge retaining a commanding 60% stake.

In addition, GL Capital will purchase 39.8 million newly issued shares from Zylox-Tonbridge at a price of HK$22 each, amounting to approximately 10.8% of the company's enlarged issued capital. Notably, this share subscription has been undertaken at a 13.5% premium over the last closing share price as of the announcement date, indicating GL Capital's confidence in Zylox-Tonbridge's future trajectory.

LifeTech’s Established Market Authority

LifeTech has solidified its standing as a leading medical device entity in China, specializing in interventions related to cardio-cerebrovascular and peripheral vascular issues. The corporation has developed an extensive lineup of endovascular solutions for addressing complex aortic conditions, along with a noteworthy range of structural heart devices. Products such as the LAmbre™ and LAxible™ left atrial appendage occluders are just a part of the cutting-edge portfolio that LifeTech has brought to market.

The impressive accolades don’t stop there, as LifeTech has introduced various first-in-class innovations like the G-Branch™ thoracoabdominal aortic stent graft system and the SureCham™ aortic arch single branch stent graft system, reinforcing its status in the industry. With over 50 medical device licenses under its belt in China and a staggering 2,608 valid patent applications, LifeTech is well-positioned to catalyze growth in this strategic partnership.

Zylox-Tonbridge's Complementary Strength

Zylox-Tonbridge, with its pioneering brands - Zylox Medical and Tonbridge Medical - brings crucial peripheral and neurovascular expertise to this collaboration. As one of the few companies providing comprehensive solutions across both segments in China, Zylox-Tonbridge has established robust research and development, manufacturing and commercialization capabilities. Since early 2025, it has initiated special review procedures for six additional products, showcasing its commitment to innovation in medical technology. With reach extending to over 3,500 hospitals nationwide, Zylox-Tonbridge is crucial for boosting healthcare accessibility in China.

Global Expansion and Competitiveness

The established international networks from both companies provide ample opportunities for joint ventures and global market expansion. Zylox-Tonbridge experienced a remarkable 349.3% surge in revenue from markets outside Mainland China during the first half of 2026. This growth is supported by a distribution network spanning over 135 countries, underlining its robust global presence. On its part, LifeTech enjoys similar success with revenue from international markets contributing to nearly 30% of its total revenue, primarily attributed to its increasing foothold in Europe and Asia.

Leadership Insights

Dr. Jonathon Zhong Zhao, Chairman of Zylox-Tonbridge, emphasized the significance of this investment, marking a pivotal milestone in their journey toward creating a top-tier integrated vascular intervention platform in China. His vision, along with the insights from GL Capital's executives, points toward mutual growth and the pursuit of excellence in medtech innovation.

This alliance stands as a testament to the potential that lies within the Chinese medical technology sector. As the partnership progresses, the market will keenly observe how this combined strength can redefine the parameters of vascular health solutions in China and beyond.

Conclusion

As Zylox-Tonbridge and GL Capital embark on this ambitious venture with LifeTech Scientific, the landscape of vascular and structural heart interventions is set to witness transformative changes. By leveraging shared resources and a collective mission, these companies are poised to make significant advancements in healthcare, fostering international competitiveness for Chinese medtech brands while delivering cutting-edge solutions for patients worldwide.